Triple negative breast cancer: a brief review of its characteristics and treatment options.
Triple negative breast cancer: a brief review of its characteristics and treatment options.
复制标题
DOI：
10.1177/0897190012442062
复制
发表时间：
2012-06-01
影响因子：
1.3
通讯作者：
Olin, Jacqueline L
中科院分区：
文献类型：
--
作者：
Griffiths, Carrie L;Olin, Jacqueline L
三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌，其特征是缺乏雌激素（ER）和孕激素受体（PRs）以及人表皮生长因子受体（HER-2）的表达，这在其他乳腺癌亚型中很常见。TNBC亚型主要发生在非裔美国人或西班牙裔的年轻女性中，肿瘤往往是高级别的，最初对化疗有反应。然而，TNBC的特点是具有高复发、转移和死亡率的侵袭性。治疗选择有限，因为通常用于其他乳腺癌的激素受体和HER-2拮抗剂无效。因此，TNBC的主要治疗方法是传统的全身细胞毒性化疗。TNBC的潜在未来治疗包括靶向分子策略，包括多腺苷二磷酸核糖聚合酶（PARP）和表皮生长因子受体（EGFR）抑制剂和抗血管生成药物。进一步的研究旨在确定TNBC独特的遗传特征，可能有助于开发其他靶向分子化疗治疗方案。
Triple negative breast cancer (TNBC), an aggressive variant of breast cancer, is characterized by lack of expression of the estrogen (ER) and progesterone receptors (PRs) and the human epidermal growth factor receptor (HER-2) that are commonly observed in other breast cancer subtypes. The TNBC subtype primarily occurs in younger women of African American or Hispanic descent and tumors tend to be high grade and initially responsive to chemotherapy. However, TNBC is characteristically aggressive with high recurrence, metastatic, and mortality rates. Treatment options are limited since the hormonal receptor and HER-2 antagonists typically used for other breast cancers are ineffective. As such, the mainstay of treatment of TNBC is traditional systemic cytotoxic chemotherapy. Potential future therapies for TNBC include targeted molecular strategies including poly (adenosine diphosphate ribose) polymerase (PARP) and epidermal growth factor receptor (EGFR) inhibitors and antiangiogenic agents. Further research aimed at identifying unique genetic characteristics of TNBC may allow development of other targeted molecular chemotherapy treatment options.